LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free CEL Stock Alerts GBX 78 0.00 (0.00%) (As of 06:30 AM ET) Add Compare Share Share Today's Range 77▼ 8050-Day Range 78▼ 12052-Week Range 73.44▼ 165Volume68,361 shsAverage Volume42,216 shsMarket Capitalization£51.28 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 235 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlines Get Celadon Pharmaceuticals alerts: Email Address Ad Weiss RatingsAre you prepared for a financial lockdown?A new kind of American dystopia is being built before our eyes, and most people have no idea what's happening. That's why I've recorded this urgent message to give you all the details on how to prepare … Including three steps to take right now.Click here to watch my video before it's too late. About Celadon Pharmaceuticals Stock (LON:CEL)Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.Read More CEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CEL Stock News HeadlinesMay 23, 2024 | lse.co.ukTRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pactFebruary 28, 2024 | morningstar.comCeladon Pharmaceuticals PLC CELDecember 14, 2023 | lse.co.ukCeladon announces start of cannabis supply for two UK companiesDecember 12, 2023 | lse.co.ukTRADING UPDATES: Celadon Pharma raises GBP2.0 million via placingDecember 4, 2023 | msn.comUK's First Medical Marijuana Clinical Trial Gets Underway: National Health Service Remains CautiousNovember 16, 2023 | lse.co.ukCeladon shares rise on supply contract worth up to GBP26 millionOctober 13, 2023 | marketwatch.comCeladon Pharmaceuticals to Raise GBP1 Mln via Discounted Placing, SubscriptionOctober 1, 2023 | finance.yahoo.comCeladon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)September 28, 2023 | lse.co.ukCeladon Pharmaceuticals interim loss narrows; optimistic for futureSeptember 5, 2023 | lse.co.ukCeladon shares rise on second UK contract win for cannabis productSeptember 5, 2023 | marketwatch.comCeladon Pharmaceuticals Enters New Contract Worth Up to GBP1.2 Mln in RevenueAugust 22, 2023 | finance.yahoo.comOwning 61% in Celadon Pharmaceuticals Plc (LON:CEL) means that insiders are heavily invested in the company's futureAugust 1, 2023 | ca.finance.yahoo.comCEL.L - Celadon Pharmaceuticals PlcAugust 1, 2023 | lse.co.ukCeladon receives approval for 5,000 patient clinical cannabis trialJune 9, 2023 | finance.yahoo.comInvestors’ Chronicle: Oxford Metrics, N Brown, Celadon PharmaceuticalsJune 5, 2023 | lse.co.ukCeladon Pharmaceuticals loss widens; confident amid three-year dealMay 30, 2023 | lse.co.ukCeladon secures GBP7 million credit facility as product demand growsMay 30, 2023 | marketwatch.comCeladon Pharmaceuticals Shares Rise on New GBP7 Mln Line of CreditMay 24, 2023 | lse.co.ukCeladon signs commercial cannabis supply agreement with UK firmMay 24, 2023 | lse.co.ukCORRECT: Celadon signs commercial cannabis supply agreement in UKApril 20, 2023 | finance.yahoo.comC15 Solutions Anticipates Substantial Growth in European Cannabis Market Through Innovative Tech PlatformMarch 15, 2023 | finance.yahoo.comJames Short Celadon Pharmaceuticals Plc's (LON:CEL) CEO is the most bullish insider, and their stock value gained 162%last weekMarch 14, 2023 | thetimes.co.ukFresh permit for cannabis lifts CeladonMarch 14, 2023 | marketwatch.comCeladon Pharmaceuticals Shares Jump as Sale of Pharmaceutical Cannabis Product GrantedJanuary 16, 2023 | thetimes.co.ukCeladon wins right to cultivate and make medicinal cannabis oilSee More Headlines Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:CEL CUSIPN/A CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 235 High Stock Price TargetGBX 235 Low Stock Price TargetGBX 235 Potential Upside/Downside+201.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-7,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-142.14% Return on Assets-34.58% Debt Debt-to-Equity Ratio148.29 Current Ratio2.62 Quick Ratio6.97 Sales & Book Value Annual Sales£11,258.00 Price / Sales4,554.73 Cash FlowGBX 25.55 per share Price / Cash Flow3.05 Book ValueGBX 5 per share Price / Book15.60Miscellaneous Outstanding Shares65,740,000Free FloatN/AMarket Cap£51.28 million OptionableNot Optionable Beta-0.02 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. James Gareth Short (Age 56)Co-Founder, CEO & Executive Director Comp: $246.15kMr. Paul AllenCo-FounderMr. Jonathan Paul Turner (Age 46)CFO & Director Iqbal GillChief Scientific OfficerMs. Kerin Williams (Age 54)Company Secretary Key CompetitorsAlliance PharmaLON:APHBeximco PharmaceuticalsLON:BXPAnimalcare GroupLON:ANCRECO Animal Health GroupLON:EAHDiurnal GroupLON:DNLView All Competitors CEL Stock Analysis - Frequently Asked Questions Should I buy or sell Celadon Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CEL shares. View CEL analyst ratings or view top-rated stocks. What is Celadon Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for Celadon Pharmaceuticals' shares. Their CEL share price targets range from GBX 235 to GBX 235. On average, they predict the company's share price to reach GBX 235 in the next year. This suggests a possible upside of 201.3% from the stock's current price. View analysts price targets for CEL or view top-rated stocks among Wall Street analysts. How have CEL shares performed in 2024? Celadon Pharmaceuticals' stock was trading at GBX 115 on January 1st, 2024. Since then, CEL stock has decreased by 32.2% and is now trading at GBX 78. View the best growth stocks for 2024 here. How do I buy shares of Celadon Pharmaceuticals? Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:CEL) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.